Current status and research progress of interventional and systemic therapy for advanced hepatocellular carcinoma

doi:10.3760/cma.j.cn371439-20230805-00142

Abstract

Abstract:

Hepatocellular carcinoma （HCC） is a common malignant tumor with high incidence and mortality rates in China. Most patients are diagnosed at an advanced stage when seeking medical treatment. Interventional therapy is the main local treatment for HCC. As a new interventional material， CalliSpheres drug-eluting microspheres have more advantages than iodipin in traditional transcatheter chemoembolization， and hepatic artery infusion chemotherapy has higher rates of remission and translation. A series of targeted drugs， such as lenvatinib， donafinib， and apatinib have been approved for application in the treatment of advanced HCC. Immune checkpoint inhibitors have made breakthroughs in the treatment of advanced HCC. Various new drugs are emerging， with clinical studies on various combinations of different therapeutic drugs being gaining new findings. This article aims to discuss the recent applications and clinical research progress of interventional therapy， targeted therapy and immunotherapy in the treatment of advanced HCC so as to provide a reference for the decision-making of HCC.

Key words: Carcinoma， hepatocellular, Molecular targeted therapy, Immune checkpoint inhibitors, Interventionaltherapy

Liu Shaoping, Luo Hanchuan, Lin Shuhan, Luo Jiahui. Current status and research progress of interventional and systemic therapy for advanced hepatocellular carcinoma[J]. Journal of International Oncology, 2023, 50(12): 758-762.

References 38

[1]	Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249. DOI: 10.3322/caac.21660.
[2]	Lyu N, Lin Y, Kong Y, et al. FOXAI: a phase Ⅱ trial evaluating the efficacy and safety of hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin for advanced hepatocellular carcinoma[J]. Gut, 2018, 67(2): 395-396. DOI: 10.1136/gutjnl-2017-314138.
[3]	Rahman FA, Naidu J, Ngiu CS, et al. Conventional versus doxorubicin-eluting beads transarterial chemoembolization for unresectable hepatocellular carcinoma: a tertiary medical centre experience in malaysia[J]. Asian Pac J Cancer Prev, 2016, 17(8): 4037-4041.
[4]	Zhang S, Huang C, Li Z, et al. Comparison of pharmacokinetics and drug release in tissues after transarterial chemoembolization with doxorubicin using diverse lipiodol emulsions and CalliSpheres beads in rabbit livers[J]. Drug Deliv, 2017, 24(1): 1011-1017. DOI: 10.1080/10717544.2017.1344336. pmid: 28660787
[5]	Wu B, Zhou J, Ling G, et al. CalliSpheres drug-eluting beads versus lipiodol transarterial chemoembolization in the treatment of hepatocellular carcinoma: a short-term efficacy and safety study[J]. World J Surg Oncol, 2018, 16(1): 69. DOI: 10.1186/s12957-018-1368-8. pmid: 29587773
[6]	周永祥, 张景俊, 罗志刚, 等. CalliSpheres^®载药微球栓塞治疗高龄肝癌患者的安全性分析[J]. 广东医学, 2018, 39(10): 1561-1565. DOI: 10.3969/j.issn.1001-9448.2018.10.030.
[7]	寸江平, 姜永能, 宗璇, 等. CalliSpheres微球联合空白微球TACE治疗中晚期肝癌的近期疗效及安全性研究[J]. 介入放射学杂志, 2019, 28(3): 237-241. DOI: 10.3969/j.issn.1008-794X.2019.03.007.
[8]	蒲长宇, 陈琦. 载药微球用于中晚期肝癌TACE术对肝功能及免疫功能的影响[J]. 肝脏, 2020, 25(1): 42-46. DOI: 10.3969/j.issn.1008-1704.2020.01.015.
[9]	郑惊雷, 梁力建, 胡文杰, 等. 区域性灌注化疗时5-FU的血液和肝脏组织药物浓度分布特征[J]. 南方医科大学学报, 2008, 28(5): 823-827. DOI: 10.3321/j.issn:1673-4254.2008.05.028.
[10]	Choi JH, Chung WJ, Bae SH, et al. Randomized, prospective, comparative study on the effects and safety of sorafenib vs. hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma with portal vein tumor thrombosis[J]. Cancer Chemother Pharmacol, 2018, 82(3): 469-478. DOI: 10.1007/s00280-018-3638-0.
[11]	Li QJ, He MK, Chen HW, et al. Hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin versus transarterial chemoembolization for large hepatocellular carcinoma: a randomized phase Ⅲ trial[J]. J Clin Oncol, 2022, 40(2): 150-160. DOI: 10.1200/JCO.21.00608.
[12]	张希昊, 章馨允, 曹曼卿, 等. 肝细胞癌的抗血管生成免疫联合介入治疗:肝动脉灌注化疗与化疗栓塞疗效的比较[J]. 外科理论与实践, 2022, 27(2): 152-157. DOI: 10.16139/j.1007-9610.2022.02.013.
[13]	He MK, Liang RB, Zhao Y, et al. Lenvatinib, toripalimab, plus hepatic arterial infusion chemotherapy versus lenvatinib alone for advanced hepatocellular carcinoma[J]. Ther Adv Med Oncol, 2021, 13: 17588359211002720. DOI: 10.1177/17588359211002720.
[14]	中国抗癌协会肝癌专业委员会转化治疗协作组. 肝癌转化治疗中国专家共识(2021版)[J]. 中国实用外科杂志, 2021, 41(6): 618-632. DOI: 10.19538/j.cjps.issn1005-2208.2021.06.02.
[15]	Lopez PM, Villanueva A, Llovet JM. Systematic review: evidence-based management of hepatocellular carcinoma—an updated analysis of randomized controlled trials[J]. Aliment Pharmacol Ther, 2006, 23(11): 1535-1547. DOI: 10.1111/j.1365-2036.2006.02932.x.
[16]	Ganten TM, Stauber RE, Schott E, et al. Sorafenib in patients with hepatocellular carcinoma-results of the observational INSIGHT study[J]. Clin Cancer Res, 2017, 23(19): 5720-5728. DOI: 10.1158/1078-0432.CCR-16-0919. pmid: 28698202
[17]	Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial[J]. Lancet, 2018, 391(10126): 1163-1173. DOI: 10.1016/S0140-6736(18)30207-1. pmid: 29433850
[18]	杨欣荣, 孙惠川, 谢青, 等. 仑伐替尼肝癌全病程应用中国专家指导意见[J]. 中华消化外科杂志, 2023, 22(2): 167-180. DOI: 10.3760/cma.j.cn115610-20230201-00035.
[19]	王俊洁, 徐龙, 袁国盛, 等. 信迪利单抗联合仑伐替尼二线治疗不可切除肝细胞肝癌的临床疗效及安全性[J]. 实用医学杂志, 2022, 38(9): 1130-1135. DOI: 10.3969/j.issn.1006-5725.2022.09.016.
[20]	秦叔逵, 毕锋, 白玉贤, 等. 多纳非尼和索拉非尼头对头一线治疗晚期肝细胞癌的药代动力学参数比较研究[J]. 临床肿瘤学志, 2022, 27(6): 481-487. DOI: 10.3969/j.issn.1009-0460.2022.06.001.
[21]	Qin S, Bi F, Gu S, et al. Donafenib versus sorafenib in first-line treatment of unresectable or metastatic hepatocellular carcinoma: a randomized, open-label, parallel-controlled phase Ⅱ-Ⅲ trial[J]. J Clin Oncol, 2021, 39(27): 3002-3011. DOI: 10.1200/JCO.21.00163.
[22]	古善智, 黄满平, 谭玉林, 等. 多纳非尼片联合抗PD-1单抗和经导管动脉化疗栓塞术治疗不可手术切除的肝细胞癌的临床研究[J]. 临床肿瘤学杂志, 2023, 28(7): 609-614. DOI: 10.3969/j.issn.1009-0460.2023.07.006.
[23]	中国临床肿瘤学会肝癌专家委员会; 中国临床肿瘤学会抗肿瘤药物安全管理专家委员会. 多纳非尼治疗肝细胞癌临床应用专家共识[J]. 临床肿瘤学杂志, 2022, 27(8): 749-757. DOI: 10.3969/j.issn.1009-0460.2022.08.013.
[24]	张珅瑜, 宋瑞鹏, 王伟, 等. 多纳非尼辅助治疗肝细胞癌术后高危复发病人安全性和有效性初步研究[J]. 中国实用外科杂志, 2023, 43(4): 401-404. DOI: 10.19538/j.cjps.issn1005-2208.2023.04.07.
[25]	Zaydfudim VM, Vachharajani N, Klintmalm GB, et al. Liver resection and transplantation for patients with hepatocellular carcinoma beyond Milan criteria[J]. Ann Surg, 2016, 264(4): 650-658. DOI: 10.1097/SLA.0000000000001866. pmid: 27433910
[26]	Qin S, Li Q, Gu S, et al. Apatinib as second-line or later therapy in patients with advanced hepatocellular carcinoma (AHELP): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial[J]. Lancet Gastroenterol Hepatol, 2021, 6(7): 559-568. DOI: 10.1016/S2468-1253(21)00109-6.
[27]	杨逸涵, 李婉慈, 仲斌演, 等. 经肝动脉化疗栓塞术联合卡瑞利珠单抗及阿帕替尼治疗中晚期肝细胞癌的效果及安全性分析[J]. 临床肝胆病杂志, 2022, 38(12): 2755-2760. DOI: 10.3969/j.issn.1001-5256.2022.12.014.
[28]	Zhou G, Boor PPC, Bruno MJ, et al. Immune suppressive checkpoint interactions in the tumour microenvironment of primary liver cancers[J]. Br J Cancer, 2022, 126(1): 10-23. DOI: 10.1038/s41416-021-01453-3.
[29]	Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma[J]. N Engl J Med, 2020, 382(20): 1894-1905. DOI: 10.1056/NEJMoa1915745.
[30]	李蓝星, 张音洁, 金永东. 靶向联合免疫治疗在不可切除肝细胞癌的临床研究进展[J]. 肿瘤预防与治疗, 2022, 35(9): 861-874. DOI: 10.3969/j.issn.1674-0904.2022.09.013.
[31]	Galle PR, Finn RS, Qin S, et al. Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial[J]. Lancet Oncol, 2021, 22(7): 991-1001. DOI: 10.1016/S1470-2045(21)00151-0.
[32]	陈凤麟, 邢宝才. 肝细胞癌的系统治疗——现状和展望[J]. 肝胆胰外科杂志, 2023, 35(1): 7-12. DOI: 10.11952/j.issn.1007-1954.2023.01.002.
[33]	Ren Z, Xu J, Bai Y, et al. Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study[J]. Lancet Oncol, 2021, 22(7): 977-990. DOI: 10.1016/S1470-2045(21)00252-7.
[34]	谭永华, 蔡江霞, 刘慧利, 等. 信迪利单抗治疗中晚期肝细胞癌的疗效及安全性[J]. 介入放射学杂志, 2023, 32(8): 750-754. DOI: 10.3969/j.issn.1008-794X.2023.08.005.
[35]	徐竟益, 钱新烨, 胡旺, 等. 术前新辅助治疗肝细胞癌完全坏死成功转化1例[J]. 中华普通外科杂志, 2023, 38(1): 65. DOI: 10.3760/cma.j.cn113855-20220803-00493.
[36]	Ren Z, Ducreux M, Abou-Alfa GK, et al. Tislelizumab in patients with previously treated advanced hepatocellular carcinoma (RATIONALE-208): a multicenter, non-randomized, open-label, phase 2 trial[J]. Liver Cancer, 2023, 12(1): 72-84. DOI: 10.1159/000527175. pmid: 36872927
[37]	Qin S, Kudo M, Meyer T, et al. LBA36 final analysis of RATIONALE-301: randomized, phase Ⅲ study of tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma[J]. Ann Oncol, 2022, 33(S7): S1402-S1403. DOI: 10.1016/j.annonc.2022.08.033.
[38]	Xu L, Chen J, Yang J, et al. 165P Efficacy and safety of tislelizumab (TIS) plus lenvatinib (LEN) as first-line treatment in patients (pts) with unresectable hepatocellular carcinoma (uHCC): a single-arm, multicenter, phase Ⅱ trial[J]. Immunooncol Technol, 2022, 16(S1): 100277. DOI: 10.1016/j.iotech.2022.100277.